NEW YORK (GenomeWeb News) – MD Anderson Cancer Center has expanded its license agreement with bioinformatics company BioDiscovery for the Nexus Copy Number microarray software platform, the company said today.
The software is used to analyze and visualize chromosomal aberrations from microarray data, and the agreement allows many users in different labs to use it at the same time. MD Anderson expanded the original site license agreement to enterprise level, BioDiscovery said.
The Nexus Copy Number platform supports a variety of microarray platforms including Agilent, Affymetrix, Illumina, GenePix, BlueFuse, ImaGene, Roche NimbleGen, Empire Genomics, and custom data files.
Financial terms of the agreement were not released.